Apellis Pharmaceuticals (NASDAQ:APLS) Insider Sells $168,173.25 in Stock

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) insider Nur Nicholson sold 7,725 shares of the stock in a transaction on Thursday, January 22nd. The stock was sold at an average price of $21.77, for a total value of $168,173.25. Following the completion of the transaction, the insider owned 71,118 shares of the company’s stock, valued at $1,548,238.86. The trade was a 9.80% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

Nur Nicholson also recently made the following trade(s):

• On Tuesday, January 20th, Nur Nicholson sold 2,203 shares of Apellis Pharmaceuticals stock. The stock was sold at an average price of $19.79, for a total value of $43,597.37.
• On Tuesday, January 13th, Nur Nicholson sold 2,618 shares of Apellis Pharmaceuticals stock. The shares were sold at an average price of $22.19, for a total transaction of $58,093.42.

Apellis Pharmaceuticals Stock Down 1.1%

Shares of NASDAQ APLS opened at $21.76 on Monday. The firm’s 50-day moving average is $23.02 and its two-hundred day moving average is $23.59. The company has a market capitalization of $2.75 billion, a PE ratio of 70.18 and a beta of 0.31. Apellis Pharmaceuticals, Inc. has a 12-month low of $16.10 and a 12-month high of $30.91. The company has a debt-to-equity ratio of 0.90, a current ratio of 3.54 and a quick ratio of 3.10.

Apellis Pharmaceuticals (NASDAQ:APLS) last released its quarterly earnings results on Thursday, October 30th. The company reported $1.67 earnings per share for the quarter, topping analysts’ consensus estimates of $1.03 by $0.64. The company had revenue of $458.58 million during the quarter, compared to analysts’ expectations of $364.58 million. Apellis Pharmaceuticals had a return on equity of 18.94% and a net margin of 4.43%.The business’s revenue for the quarter was up 133.0% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.46) earnings per share. Equities analysts anticipate that Apellis Pharmaceuticals, Inc. will post -1.7 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the company. Hennion & Walsh Asset Management Inc. raised its stake in Apellis Pharmaceuticals by 7.9% during the fourth quarter. Hennion & Walsh Asset Management Inc. now owns 51,933 shares of the company’s stock worth $1,305,000 after acquiring an additional 3,804 shares during the period. SG Americas Securities LLC boosted its position in Apellis Pharmaceuticals by 35.9% during the 4th quarter. SG Americas Securities LLC now owns 567,046 shares of the company’s stock valued at $14,244,000 after purchasing an additional 149,654 shares during the period. Diversified Trust Co. acquired a new position in Apellis Pharmaceuticals during the 4th quarter valued at approximately $476,000. Wedmont Private Capital grew its stake in Apellis Pharmaceuticals by 4.1% during the 4th quarter. Wedmont Private Capital now owns 11,883 shares of the company’s stock worth $315,000 after buying an additional 468 shares during the last quarter. Finally, Allworth Financial LP increased its position in Apellis Pharmaceuticals by 64.1% in the third quarter. Allworth Financial LP now owns 2,194 shares of the company’s stock worth $50,000 after buying an additional 857 shares during the period. Institutional investors and hedge funds own 96.29% of the company’s stock.

More Apellis Pharmaceuticals News

Here are the key news stories impacting Apellis Pharmaceuticals this week:

• Positive Sentiment: BofA upgraded APLS to Buy and cited a stronger-than-expected launch trajectory for Apellis’s newly approved kidney-disease therapy, assigning a $28 price target — a vote of confidence that implies material upside if commercial momentum continues. Apellis Raised to Buy at Bank of America
• Positive Sentiment: An analyst note highlights early uptake of Empaveli and argues current valuation understates its revenue potential; continued strong launch metrics could drive a re‑rating and support upside from current levels. Apellis Valuation Ignores Empaveli Potential, Says Analyst
• Neutral Sentiment: Wells Fargo trimmed its price target (from $29 to $26) but kept an Overweight rating — a mixed signal that reduces upside expectations while leaving institutional support intact. Wells Fargo lowers price target on Apellis
• Neutral Sentiment: RBC Capital reiterated a Hold rating, a neutral stance that may temper buying interest from investors seeking stronger analyst conviction. RBC Capital Sticks to Its Hold Rating for Apellis Pharmaceuticals (APLS)
• Negative Sentiment: Multiple senior insiders — including CEO Cedric Francois, CFO Timothy Sullivan, General Counsel David Watson and others — filed Form 4 sales on Jan. 20–22 (large, clustered disposals totaling many tens of thousands of shares). Even if routine (diversification or option-related), clustered executive selling typically weighs on near‑term sentiment and likely contributed to the stock decline. See CEO filing for details. CEO Cedric Francois Form 4

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on the stock. Robert W. Baird lifted their price target on shares of Apellis Pharmaceuticals from $50.00 to $52.00 and gave the company an “outperform” rating in a research report on Friday, October 31st. Needham & Company LLC cut their target price on shares of Apellis Pharmaceuticals from $29.00 to $28.00 and set a “buy” rating on the stock in a research note on Tuesday, January 13th. Wolfe Research assumed coverage on shares of Apellis Pharmaceuticals in a report on Thursday, November 6th. They set a “peer perform” rating on the stock. Cantor Fitzgerald lowered their price target on Apellis Pharmaceuticals from $39.00 to $35.00 and set an “overweight” rating for the company in a report on Tuesday, January 13th. Finally, The Goldman Sachs Group reissued a “sell” rating and issued a $19.00 price objective on shares of Apellis Pharmaceuticals in a research report on Monday, January 12th. Twelve investment analysts have rated the stock with a Buy rating, six have given a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, Apellis Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average price target of $33.53.

About Apellis Pharmaceuticals

Apellis Pharmaceuticals, Inc, traded as NASDAQ:APLS, is a clinical-stage biopharmaceutical company focused on the development of novel therapies targeting the complement cascade for the treatment of rare and debilitating diseases. The company’s research and development efforts center on modulating complement proteins to address a range of ophthalmologic, hematologic and renal conditions. Apellis leverages its proprietary compstatin technology platform to design targeted inhibitors intended to improve patient outcomes and quality of life.

The company’s lead marketed product, Syfovre (pegcetacoplan), is an intravitreal complement C3 inhibitor approved for geographic atrophy secondary to age-related macular degeneration, with ongoing investigations in other retinal disorders.